Engaging the immune system promises to be a key component of optimal cancer therapy 1 . Despite effective strategies to elicit an immune response, effective tumor control depends in part on the ability of tumor-reactive T cells to infiltrate tumors. Patients with cancer who have high levels of intratumoral T cells experience significantly increased survival across multiple tumor types [2] [3] [4] [5] [6] , and experimentally, T cell infiltration is critical for optimal anti-tumor immunity and tumor elimination [7] [8] [9] . Tumors exploit complex biological programs linking angiogenesis and immune evasion 10, 11 , and tumor angiogenesis is often associated with suppression of T cell-mediated tumor rejection 2,12,13 . The factors driving angiogenesis exert much of their action through the endothelium, and we 14 and others 15 have found that under their influence, the tumor endothelium establishes a substantial barrier that limits T cell infiltration, which we named the tumor endothelial barrier. Thus, efficacious cancer immunotherapy depends on developing strategies to dismantle the tumor endothelial barrier.
Engaging the immune system promises to be a key component of optimal cancer therapy 1 . Despite effective strategies to elicit an immune response, effective tumor control depends in part on the ability of tumor-reactive T cells to infiltrate tumors. Patients with cancer who have high levels of intratumoral T cells experience significantly increased survival across multiple tumor types [2] [3] [4] [5] [6] , and experimentally, T cell infiltration is critical for optimal anti-tumor immunity and tumor elimination [7] [8] [9] . Tumors exploit complex biological programs linking angiogenesis and immune evasion 10, 11 , and tumor angiogenesis is often associated with suppression of T cell-mediated tumor rejection 2, 12, 13 . The factors driving angiogenesis exert much of their action through the endothelium, and we 14 and others 15 have found that under their influence, the tumor endothelium establishes a substantial barrier that limits T cell infiltration, which we named the tumor endothelial barrier. Thus, efficacious cancer immunotherapy depends on developing strategies to dismantle the tumor endothelial barrier.
So far, studies investigating the tumor endothelial barrier have focused largely on endothelial-T cell adhesive interactions regulating T cell trafficking. Potent proangiogenic growth factors, including VEGF-A, attenuate endothelial-T cell adhesion through deregulation of vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 in endothelial cells 16, 17 . In addition, the endothelinendothelin B receptor (ET B R) pathway, which is involved in vascular regulation, limits T cell adhesion to the endothelium. Experimentally, blockade of VEGF-A 8 or ET B R 14 increases the amount of T cell infiltration in tumors and enhances immune therapy. Emerging evidence suggests that the endothelium acts as a selective barrier, allowing certain T cell subsets, notably T reg cells, to traffic more effectively 18 . However, the studies described above have not explored this differential regulatory role of the tumor endothelium.
FasL is an established homeostatic mediator of T cell apoptosis 19 and is also reportedly expressed on the tumor endothelium of humans 20 and mice 21 . Transgenic overexpression of FasL on normal endothelium has been shown to impair T cell infiltration in transplant 22 and ischemia-reperfusion-injury mouse models 23 . Here we demonstrate that FasL can be expressed specifically by the vasculature of human solid tumors and is upregulated by the cooperative action of proangiogenic and immunosuppressive paracrine factors in the tumor microenvironment. In humans, endothelial FasL expression was associated with the absence of intratumoral CD8 + T (but not T reg ) cells, whereas in mice, endothelial FasL impaired T cell infiltration in tumors in a selective manner, leading to preferential killing of tumorreactive CD8 + T effector but not T reg cells, thereby establishing a CD8-to-FoxP3 T cell ratio that facilitates tumor growth. Pharmacologic inhibition of such factors attenuated tumor endothelial FasL expression, produced a substantial increase in CD8 + T cell infiltration and led to CD8-dependent tumor growth suppression in mice. This work provides new insights into a selective endothelial immune barrier, which establishes immune tolerance in tumors.
RESULTS

The human tumor endothelium expresses FasL
We analyzed expression of FasL in tissue microarrays (TMAs) containing over 600 samples of human breast, colon, renal, bladder, prostate a r t i c l e s 6 0 8 VOLUME 20 | NUMBER 6 | JUNE 2014 nature medicine or ovarian adenocarcinomas (Supplementary Table 1 ) and control TMAs derived from normal organs using well-validated antibodies ( Supplementary Fig. 1 ). In agreement with others 20 , normal organ vasculature expressed no FasL ( Fig. 1a and Supplementary Fig. 2 ), whereas a substantial percentage of CD34 + blood vessels expressed FasL in primary and metastatic tumors ( Fig. 1a-d and Supplementary Fig. 3a ).
In line with previous reports 24 , in some tumors, we also detected high levels of FasL in the tumor cells themselves ( Supplementary Fig. 3b-d) , but in the majority of tumors, the tumor cells expressed no or low levels of FasL ( Fig. 1 and Supplementary Fig. 3c,d) . Thus, FasL expression in most tumors is relatively specific to the tumor endothelium. We verified surface FasL expression on freshly isolated CD45 − CD31 + tumor endothelial cells (TECs) from ovarian cancers (Fig. 1c,d) .
We previously reported an unexplained dichotomy between tumor islets and tumor stroma with respect to T cell infiltration in ovarian cancer: although the vast majority of ovarian cancers exhibit T cell infiltration in the stroma, only a proportion of tumors exhibit T cells infiltrating tumor islets (intraepithelial or intratumoral T cells) 2 . We examined endothelial FasL expression in tumor islets and the surrounding stroma of patients with ovarian cancer. FasL expression on the endothelium within tumor islets was significantly (P < 0.001) higher compared to the endothelium in the surrounding stroma, which expressed significantly lower or no FasL (Fig. 1e,f) . This suggests a tight regulation of FasL expression in tumors and implies an important role in regulating intratumoral T cell infiltration.
Human endothelial cells expressing FasL kill effector T cells
Because FasL is a known death ligand for activated T cells, we tested whether endothelial cells freshly isolated from tumors can kill activated T cells. We isolated TECs from human ovarian cancer samples and co-incubated them with tumor-associated T lymphocytes isolated from autologous ascites, which were previously activated with phorbol myristate acetate and ionomycin (PMA/ionomycin). We found that TECs killed autologous tumor-associated T lymphocytes, an effect that was attenuated by FasL-blocking antibody (Fig. 2a) .
Because the fate of the anti-tumor immune response depends on the balance between T effector (T eff ) and T reg cells in tumors, we asked whether endothelial FasL affects various T cell subsets differently. We transduced an immortalized human microvascular endothelial cell line (HMEC-1) with either GFP or FasL and incubated these cells with different human T cell subsets purified from peripheral blood of normal donors. As expected, unstimulated T cells were insensitive to killing by FasL + HMEC-1 cells. However, after stimulation with a CD3-specific antibody and IL-2 for 72 h, both CD8 + and CD4 + CD25 − T cells were sensitized to FasL killing. Notably, CD4 + CD25 + cells were largely resistant to FasL killing (Fig. 2b) . Killing of activated T cells required as little as 15 min of co-incubation with FasL + HMEC-1 cells, highlighting the biological relevance of this interaction (data not shown). These results suggest that the tumor endothelium FasL has a critical role in regulating the balance between T eff and T reg cells in tumors.
We then examined the mechanisms of T reg cell resistance to FasL killing. Compared to CD8 + and CD4 + CD25 − T cells, CD4 + CD25 + cells expressed higher levels of several anti-apoptotic genes, including BCL2, BCLx L and the FADD-like IL-1β-converting enzyme-inhibitory protein (c-FLIP) (Fig. 2c) . Using shRNA, we found that knockdown of c-FLIP S and c-FLIP L , but not BCL2 or BCLx L , in T reg cells enhanced their sensitivity to endothelial FasL (Fig. 2d) . Vice versa, we found that transduction of CD8 + and CD4 + CD25 − T cells with either c-FLIP S or c-FLIP L increased resistance to FasL-mediated apoptosis, whereas transduction with BCL2 or BCLx L had no effect (Fig. 2e) . Thus, c-FLIP mediates FasL resistance in T cells, and enhanced c-FLIP expression is responsible for FasL resistance in T reg cells. We examined human tumors for associations between endothelial FasL and T cell subsets. In an ovarian cancer cohort, similarly to previous observations 2 , intraepithelial CD3 + or CD8 + cells were associated with significant (P = 0.027 and P = 0.019, respectively) increases in overall survival (Supplementary Fig. 4a,b) , and a high percentage of FasL + vessels in tumor islets was associated with fewer intraepithelial CD3 + cells (Supplementary Fig. 4c ). This difference in CD3 + numbers was due largely to CD8 + cells, as tumors exhibiting a high percentage of FasL + vessels lacked intraepithelial CD8 + tumor-infiltrating lymphocytes (TILs) but contained intraepithelial FoxP3 + cells (Fig. 2f,g and Supplementary Fig. 4c) . Notably, we found no correlation of intraepithelial CD8 + cell numbers and FasL expression by tumor cells (Supplementary Fig. 4d ). We extended these observations to additional tumor types and found that endothelial cell, but not tumor cell, expression of FasL was associated with fewer CD8 + cells in colon, bladder, prostate and renal cancers but not in breast cancer ( Fig. 2g and Supplementary Fig. 4e) . Thus, the tumor endothelium upregulates FasL and acquires the ability to selectively eliminate T eff cells while allowing the accumulation of T reg cells, a phenomenon that appears to be preserved across several solid tumor types.
Tumor-derived factors induce endothelial FasL expression
The compartmentalized expression of endothelial FasL in tumors (Fig. 1e,f) suggests a tight regulation by local factors. To test the hypothesis that paracrine factors produced by tumor cells upregulate endothelial FasL, we treated human microvascular endothelial cells (HMVECs) in vitro with ovarian cancer ascites, which contains tumor-derived soluble factors. We collected ascites supernatants from 20 individuals with ovarian cancer. Approximately half of the supernatants were sufficient to induce FasL in HMVECs in vitro (Fig. 3a) . We next exposed HMVECs in vitro to supernatants of 13 ovarian cancer cell lines maintained under normoxic or hypoxic conditions. Normoxic supernatants of some cell lines were able to induce FasL expression, whereas supernatants from hypoxic cells induced higher expression of FasL in HMVECs (Fig. 3b,c) . Thus, tumor-derived factors (in part hypoxia related) are responsible for the induction of endothelial FasL.
We screened known tumor-derived factors such as endothelin-1, reactive oxygen species, transforming growth factor-β (TGF-β) and VEGF-A and found that they were unable to induce FasL directly in HMVECs ( Fig. 3d and Supplementary Fig. 5 ). However, IL-10 and PGE 2 had a direct effect, which was augmented by VEGF-A, and we found significant positive interactions among these three factors ( Fig. 3d and Supplementary Fig. 5f,g ). We were unable to detect any soluble FasL in the supernatant of treated cells by ELISA (data not shown), which is in line with the observation that tumor endothelial cells retain FasL on their surface 21 . We next confirmed that treatment with the PGE 2 , VEGF-A and IL-10 cocktail was sufficient to enable HMVECs to kill Jurkat T cell targets through FasL in vitro (Fig. 3e) . Accordingly, we found a positive correlation between the ability of ascites supernatants to induce FasL expression in HMVECs in vitro and the paucity of intraepithelial TILs in matched ovarian cancer samples in vivo (Fig. 3f) . We sought to inhibit induction of FasL through available pharmacologic means. VEGF-A inhibition using a VEGF-A-neutralizing antibody was sufficient to prevent FasL induction by supernatants collected under hypoxic conditions from some, but not all, ovarian cancer cell lines (Fig. 3g) . We used acetylsalicylic acid (ASA) as a means to inhibit cyclooxygenase 1 (COX1) and COX2 activity and PGE 2 production. ASA treatment entirely abrogated FasL induction by OV68-4 supernatants, but both ASA and the VEGF-A-neutralizing antibody were required to block FasL induction by OVCAR3 supernatants (Fig. 3h) . The ability to abrogate FasL induction using a single inhibitor (either VEGF-A-neutralizing antibody or ASA) depended largely on the relative level of COX enzyme expression (Supplementary Fig. 6 ). Cell lines with high COX1 expression were able to induce FasL in the presence of a VEGF-A-neutralizing antibody, and lines with lower expression of COX-1 were not. Thus, although VEGF-A is neither sufficient nor absolutely required, its presence contributes to a robust induction of FasL expression in endothelial cells in vitro when combined with paracrine tumor microenvironment factors. 
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COX and VEGF regulate endothelial FasL expression in vivo
We analyzed VEGF-A, COX1 and COX2 expression in tumors from individuals with ovarian cancer in order to determine whether a relationship to endothelial FasL expression exists (Fig. 4a) . The majority of ovarian cancer samples were negative for COX2, as noted by others 25 and in agreement with our cell line data ( Supplementary  Fig. 6 ). COX1 was expressed at high levels by tumor cells, as reported by others 25 (Supplementary Fig. 7a ). In our cohort, VEGF-A was highly expressed by tumor cells in the majority of samples (Supplementary Fig. 7a) . COX1 expression or coexpression of COX1 and VEGF-A was associated with an increased percentage of FasLpositive vessels in tumor islets (Fig. 4b) . Furthermore, reanalysis of Affymetrix data from microdissected TECs 14 revealed correlations between endothelial FasL and the expression of PGE 2 and VEGF receptors by tumor endotheial cells (Supplementary Fig. 7b ). Thus, COX1 and VEGF-A are coexpressed and may regulate endothelial FasL expression in human ovarian cancer. Next we analyzed these mechanisms in vivo using established mouse tumor models, including the ID8-VEGF mouse ovarian cancer model 26 , as well as models of colon cancer (CT26), renal cell cancer (Renca) and melanoma (B16). ID8-VEGF cells express high levels of Vegf-a and prostaglandin in vitro (Supplementary Fig. 8a,b) but express no FasL in vitro or in vivo ( Fig. 4c and Supplementary Fig. 8c-e) . Corroborating our observations in humans, the endothelium of subcutaneous (s.c.) or intraperitoneal (i.p.) ID8-VEGF tumors expressed surface FasL (Fig. 4c-g and Supplementary Fig. 9a ), whereas FasL was absent from endothelial cells in normal mouse tissues (Supplementary Fig. 9a) . Notably, CD45 − CD31 + endothelial cells were the predominant FasLexpressing cell type in tumors (Supplementary Fig. 9b ). Although we detected FasL in some CD45 + cells (Supplementary Fig. 9b ), these FasL + cells were rare, as determined by immunohistochemistry (IHC) (Fig. 4c) , and their origin from contaminating peripheral blood cells from the tumor dissociation could not be excluded. We observed similar data in the other three tumor models (data not shown).
Therapeutic administration of the Vegf-a-specific antibody G6-31 combined with ASA reduced the overall number and percentage of FasL-positive tumor vessels in all the tumor models in vivo (Fig. 4e-g ). Use of indomethacin or sulindac sulfide instead of ASA to inhibit Cox enzymes or blockade of Vegf signaling with SU-5416 also reduced FasL expression (Supplementary Fig. 10b ). Vegf-a blockade and Cox inhibition attenuated FasL expression only in tumor endothelial cells but not in tumor-associated CD45 + cells (Supplementary Fig. 9b,c) , indicating independent regulatory mechanisms. Notably, combinatorial Vegf-a blockade and Cox inhibition (ASA) resulted in significant tumor growth suppression in all tumor models in vivo (Fig. 4h,i) . Thus, as in human solid tumors, the mouse tumor endothelium upregulates FasL, which can be attenuated by blockade of Cox plus Vegf-a.
Endothelial FasL prevents CD8 + cell infiltration in mice
We tested whether tumor endothelial FasL regulates the infiltration of CD8 + T eff cells as compared to T reg cells in vivo. Freshly isolated
TECs from ID8-VEGF tumors, which express FasL (Fig. 4c,e) , killed activated C57BL/6 splenic T cells in a dose-dependent manner in vitro (Fig. 5a) T cells (CD8/T reg ) ( Fig. 5b and Supplementary Fig. 11a,b) . Further, Fas-FasL signaling abrogation resulted in reduced tumor volumes compared to controls (Fig. 5c) . Thus, disruption of Fas-FasL interactions enhances the infiltration of T cells to tumors and improves the balance between T eff and T reg cells, which affects tumor growth. Next we found that pharmacologic inhibition of Vegf-a with the G6-31 antibody and inhibition of Cox enzymes with ASA was sufficient to induce a significant increase in tumor-infiltrating CD8 + T cells, whereas T reg cells remained unaltered in multiple tumor models ( Fig. 5d and Supplementary Figs. 10b and 11c) . The frequency of CD8 + cells in tumors was negatively correlated with the number of FasL-positive vessels in these experiments ( Fig. 5e and Supplementary Fig. 10d) . In corroboration of evidence that immune effector mechanisms were activated after FasL attenuation, we observed a highly oligoclonal T cell receptor (TCR) repertoire of T cells in the tumors of mice treated with a Vegf-a-specific antibody and ASA, with shared TCR sequences among mice, indicating responses to immunodominant tumor epitopes (Fig. 5f) . Furthermore, we observed a substantial increase in interferon-γ (IFN-γ) and granzyme-B mRNA expression in tumors of mice treated with Vegf-a-specific antibody and ASA for 5 weeks (Fig. 5g) .
To determine whether FasL ectopically expressed on the endothelium can prevent CD8 + T cell infiltration during treatment with Vegf-a-specific antibody and ASA, we used a chimeric transplantation model in which we co-injected MS1 endothelial cells that were transduced (or not) with mouse FasL and ID8-VEGF tumor cells. This model allows for the development of vessels that are developed largely by exogenous MS1 cells in vivo 27, 28 (Supplementary Fig. 12 ). Tumors enriched with control MS1 cells responded to treatment with Vegfa-specific antibody and ASA, which increased CD45 + CD3 + CD8 + TILs and resulted in significant tumor suppression (Fig. 5h) . In contrast, tumors enriched with MS1 cells with exogenous expression of FasL were resistant to treatment with Vegf-a-specific antibody and ASA, which did not increase intratumoral CD45 + CD3 + CD8 + T cells (Fig. 5h) compared to untreated controls. Therefore, the therapeutic effect of treatment with ASA and VEGF-A-specific antibodies is mediated by abrogation of endothelial FasL, which enables CD8 + T cell infiltration in tumors.
Cox and Vegf blockade promotes tumor-suppressing immunity
We examined whether the changes in CD8 + infiltrate caused by administration of the combination of Vegf-a-specific antibody and ASA was responsible for controlling the growth of tumors. The combined pharmacologic inhibition of Vegf-a and prostaglandin had a strong therapeutic effect on s.c. (Fig. 4h,i) as well as i.p. ID8-VEGF tumors (Supplementary Fig. 13a ). In the latter model, the treatment delayed ascites accumulation and significantly prolonged mouse survival (P < 0.001). Treatment with indomethacin or sulindac sulfide instead of ASA to inhibit Cox enzymes or blockade of Vegf signaling with SU-5416 also delayed tumor growth similarly ( Supplementary  Fig. 10a ). The addition of IL-10 blockade did not significantly (P = 0.143) improve inhibition of tumor growth in this setting (Supplementary Fig. 13b ). FasL-positive vessels were positively correlated with tumor volume across all mouse groups (r = 0.353, P = 0.0066). The expression of FasL in CD45 + cells had no relationship to tumor size in mice (Supplementary Fig. 9e ). CD8 cell density ( Fig. 5e and Supplementary Fig. 10e ) as well as the levels of IFN-γ and granzyme-B mRNA in tumors (Supplementary Fig. 14) were negatively correlated with tumor volume across all tumor models treated with a Vegf-a-specific antibody and ASA, suggesting cytotoxic T lymphocyte-mediated tumor suppression. To test whether the abovedescribed pharmacologic combination depended on mobilization of anti-tumor immunity, we depleted CD8 + cells, CD4 + cells or both subsets. Depletion of CD8 + cells, but not CD4 + cells, abrogated the ability of the Vegf-a-specific antibody and ASA combination to inhibit tumor growth (Fig. 5i,j) . Interestingly, 25% (2/8) of mice depleted of CD4 + cells completely eliminated their tumors, and overall CD4 + depletion enhanced anti-tumor immunity (Fig. 5j) , consistent with prior reports indicating that this effect is due to depletion of T reg cells 29 . FasL blockade synergizes with adoptive T cell transfer To further test whether endothelial FasL affects the homing of tumorreactive T cells, we performed adoptive transfer experiments using donor T cells from syngeneic mice previously vaccinated with a whole tumor-lysate vaccine 14 . We purified donor T cells from splenocytes of vaccinated mice, labeled them with carboxyfluorescein succinimidyl ester (CFSE) and transferred them into recipient mice, which were not irradiated to avoid endothelial activation 30 . We pretreated tumor-bearing WT mice either with ASA plus Vegf-a-specific antibody or with FasL-specific antibody for 48 h, injected donor T cells and continued treatment for an additional 48 h. Further, we also used Fasl gld tumor-bearing mice as recipients. We found that vaccine-primed CD8 + T cells infiltrated tumors to a higher degree in the two treatment groups and in Fasl gld mice compared to untreated WT controls (Fig. 6a-c) . Notably, there was a higher frequency of apoptotic T cells (annexin V + CFSE + CD8 + ) isolated from dissociated tumors of control mice compared to those from the treatment groups or Fasl gld mice (Fig. 6d) . In spite of these obvious differences in tumor-infiltrating T cells, we detected no difference in T cell homing or survival in spleens between control and treated mice (data not shown), with the exception of marginally increased survival of spleen T cells in Fasl gld recipient mice.
To determine whether the enhanced T cell homing and survival observed under conditions of inhibiting FasL could affect mouse survival, we performed adoptive transfer experiments using activated OT-1 cells in mice inoculated with ovalbumin (OVA)-expressing ID8-VEGF cells (Fig. 6e) . We found that adoptive transfer of activated OT-1 cells in Fasl gld mice or WT mice pretreated with ASA plus Vegf-a-specific antibody significantly prolonged survival compared to controls (P < 0.001). Thus, inhibiting endothelial FasL expression is a robust therapeutic maneuver that enhances the potency of adoptive transfer of anti-tumor T cells.
DISCUSSION
An emerging paradigm supported by our recent work 10, 11 is that angiogenesis and immune suppression are two facets of a linked biological program. Tumors co-opt existing mechanisms that are normally required to limit excessive inflammation and promote tissue recovery during infection or wound healing, and the execution of this program sustains tumor growth and promotes immunological tolerance. The tumor endothelium is a prime example of this concept, and existing work has focused largely on the angiogenic tumor endothelium as a physical passive barrier, preventing T cell extravasation and effective anti-tumor immunity 8, 10, 14 . However, new evidence suggests that the tumor endothelium is also an active immune regulator that can directly suppress T cell function 31 . Our current work expands this hypothesis with the demonstration that angiogenic growth factors induce FasL expression on the tumor endothelium, which uniquely promotes an immunosuppressive and tolerogenic environment through preferential killing of tumor-reactive CD8 + cells.
FasL has an extensive history as a mediator of immune privilege, although this idea has been controversial, particularly in the context of tumor biology 32 . Chemical alteration 33 and cellular location of expression (i.e., membrane or soluble) 34 can substantially affect the biological activity of FasL. Membrane expression of FasL is highly cytotoxic 34 , whereas soluble FasL may exert full cytotoxicity only in oxygen-rich environments 33 . In the current study, we found tumor cell expression of FasL by IHC but were unable to detect surface expression on epithelial cell adhesion molecule (EpCAM) + tumor cells by flow cytometry (data not shown). Furthermore, a panel of ovarian cancer cell lines did not express surface FasL (data not shown). This observation recapitulates several reports noting a lack of surface expression of FasL by tumors and tumor cell lines 35, 36 , and although it has been suggested that FasL-containing exosomes may contribute to T cell apoptosis and immune privilege 36 , the importance of this mechanism in vivo is unknown. We observed a strong inverse association between vessel FasL expression and CD8 + TILs, but we observed no relationship across multiple tumor types with respect to CD8 + TILs and expression of FasL by tumor cells. This observation is not without precedent 37, 38 , and we attribute this phenomenon to a greater cytotoxicity of membrane-expressed FasL on the tumor endothelium in both patients and mice.
Numerous investigators have noted that during immunotherapy, anti-tumor T cells could be found in abundance in the periphery but that often these cells failed to penetrate the tumor in large numbers [39] [40] [41] . Enhanced tumor angiogenesis is commonly associated with absence of tumor-infiltrating T cells in patients 2, 12 , and multiple investigators have determined that inhibition of angiogenesis promotes infiltration of anti-tumor T cells during adoptive therapy 8, 14, 42 . Mechanistically, existing data indicate that angiogenesis can reduce endothelial adhesion and migration of T cells 16, 17, 43 . In agreement with others, overall intratumoral T cell numbers were increased after angiogenesis blockade, but this effect was restricted largely to CD8 + T cells, as FoxP3 + cell numbers remained unchanged. Further, in mice that were either deficient in Fas-FasL signaling or treated with a FasL-specific antibody, intratumoral CD8 + T cell numbers were increased and tumor volumes were decreased independently of any effect on angiogenesis. Thus, we conclude that blocking tumor angiogenesis primarily promotes effector CD8 + T cell infiltration by limiting effector T cell apoptosis mediated by FasL expression on the tumor endothelium. These observations are particularly relevant for ex vivo-activated T cells used for adoptive cell therapy, as well as for endogenous T cells activated in lymph nodes by cancer vaccines, as T cells are highly susceptible to FasL-mediated apoptosis after activation.
VEGF-A and prostaglandins exert immunosuppression through diverse mechanisms 10 , so it is not surprising that treatment with VEGF-A-specific antibody and aspirin enhanced anti-tumor immunity. The finding, supported by others 42 , that the effect of angiogenesis blockade on tumor growth required CD8 + T cells supports the notion that factors such as VEGF-A do not simply promote tumor growth through angiogenesis. Notably, although VEGF-A-specific antibody and aspirin could inhibit angiogenesis directly, effective tumor control remained dependent on an anti-tumor T cell response. Furthermore, we found that when FasL was ectopically expressed on the endothelium, it prevented infiltration of CD8 + T cells and prevented decreases in tumor growth despite effective treatment with angiogenesis inhibitors. Therefore, the roles of VEGF-A and COX1 in promoting tumor growth are not solely mediated by their classical roles in angiogenesis and instead extend to vascular mechanisms controlling mobilization of anti-tumor immunity.
The regulation of FasL expression by the endothelium is complex, and the integration of multiple tumor microenvironment growth factors leads to optimal FasL expression by the endothelium. Therefore, although VEGF-A or PGE 2 alone are not sufficient for endothelial FasL expression, each is required for maximal induction. Thus, inhibition of FasL expression using single blockade (inhibition of either VEGF-A or COX) can be observed. We are actively pursuing the identification of the responsible signaling pathways in endothelial cells in the hopes of achieving optimal disruption of FasL expression.
Immunotherapy and anti-angiogenesis therapy have often been pursued as monotherapies. We have shown here how adoptive T cell npg transfer combined with aspirin and a VEGF-A-specific antibody led to superior infiltration of tumor-reactive T cells. This combinatorial approach is supported by previous experimental work showing enhanced control of tumor growth using a tumor lysate vaccine and ET B R blockade 14 , a tumor lysate-pulsed dendritic cell vaccine with COX2 inhibitors 44 or adoptive T cell therapy with a VEGF-Aspecific neutralizing antibody 8 . Further, similar additive benefits were observed in patients by combining recombinant IFN-α therapy and bevacizumab for the treatment of metastatic renal cell carcinoma 45 . Therefore, because of the intimate relationship between angiogenesis and immunosuppression and the likely overwhelming redundancy of pathways controlling both mechanisms, combinatorial strategies inhibiting both arms will be required for effective tumor control.
METHODS
Methods and any associated references are available in the online version of the paper. 
